Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q4 2017 · 10-K
Revenue$8.79M$8.79M+3.2% vs Q4 2016 Net Income-$21.51M-$21.51MN/M vs Q4 2016 EPS Diluted-$0.24-$0.24N/M vs Q4 2016 Operating Income-$22,887,789N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,826,473N/M Margins · derivedOperating margin-260.5%+2.2 pt vs Q4 2016
Net margin-244.7%+63.4 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 14, 2018 · 73 d after period end